$0.28
8.76% today
Nasdaq, Apr 04, 08:46 pm CET
ISIN
US6904691010
Symbol
OVID
Sector
Industry

Ovid Therapeutics Inc. Stock price

$0.30
-0.19 38.90% 1M
-0.83 73.33% 6M
-0.63 67.72% YTD
-2.75 90.12% 1Y
-3.01 90.89% 3Y
-2.47 89.12% 5Y
-11.95 97.54% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-0.04 11.35%
ISIN
US6904691010
Symbol
OVID
Sector
Industry

Key metrics

Market capitalization $21.42m
Enterprise Value $-16.90m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.30
EV/Sales (TTM) EV/Sales -29.65
P/S ratio (TTM) P/S ratio 37.58
P/B ratio (TTM) P/B ratio 0.31
Revenue growth (TTM) Revenue growth 44.50%
Revenue (TTM) Revenue $570.00k
EBIT (operating result TTM) EBIT $-61.88m
Free Cash Flow (TTM) Free Cash Flow $-56.03m
Cash position $53.08m
EPS (TTM) EPS $-0.37
P/E forward negative
P/S forward 74.60
EV/Sales forward negative
Short interest 1.82%
Show more

Is Ovid Therapeutics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Ovid Therapeutics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Ovid Therapeutics Inc. forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Ovid Therapeutics Inc. forecast:

Buy
100%

Financial data from Ovid Therapeutics Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
0.57 0.57
46% 46%
100%
- Direct Costs 0.60 0.60
63% 63%
105%
-0.03 -0.03
98% 98%
-5%
- Selling and Administrative Expenses 25 25
12% 12%
4,367%
- Research and Development Expense 36 36
29% 29%
6,379%
-61 -61
6% 6%
-10,751%
- Depreciation and Amortization 0.60 0.60
63% 63%
105%
EBIT (Operating Income) EBIT -62 -62
4% 4%
-10,856%
Net Profit -26 -26
50% 50%
-4,637%

In millions USD.

Don't miss a Thing! We will send you all news about Ovid Therapeutics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ovid Therapeutics Inc. Stock News

Neutral
GlobeNewsWire
24 days ago
Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and move its first KCC2 direct activator into the clinic Topline results from Phase 1 study of OV329 expected in Q3 2025, which will include biomarkers that measure clinical effect and target engagement, saf...
Neutral
GlobeNewsWire
about one month ago
NEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need, today announced the appointment of Stelios Papadopoulos, Ph.D. to its Board of Directors.
Neutral
GlobeNewsWire
about one month ago
NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, today announced that Meg Alexander, President and Chief Operating Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 3:10 p.m. ET in Boston, Massachuse...
More Ovid Therapeutics Inc. News

Company Profile

Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.

Head office United States
CEO Jeremy Levin
Employees 23
Founded 2014
Website www.ovidrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today